Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in SpainJuan Berenguer, Pablo Ryan, María Yllescas et al.|Clinical Microbiology and Infection|2020Cited by 423
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)Jesús Rodríguez‐Baño, María Paz García Butenegro, Pablo Ryan et al.|Clinical Microbiology and Infection|2020Cited by 128
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort studyBelén Gutiérrez‐Gutiérrez, Chiara Fanciulli, Alberto M. Borobia et al.|The Lancet Infectious Diseases|2021Cited by 104
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, M. A. von Wichmann, Esteban Ribera et al.|Clinical Infectious Diseases|2017Cited by 103
Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC scoreJuan Berenguer, José Ramón Arribas, Alberto M Borobia et al.|Thorax|2021Cited by 97